Dr Carolyn Luscombe, Head of Research and Development, has received an award at the HIV DART and Emerging Viruses 2018 in Miami, Florida for the presentation entitled“BIT225-009: Significant Immunological Outcomes after 12 weeks of BIT225 and Antiretroviral Therapy in an HIV-1 Phase 2 Clinical Trial”.
The award is an acknowledgement of the importance of the outcomes from the Phase 2 trial data presented, as well as the robustness of the science underlying the Company’s programs.
Thank you for your interest in Biotron.
Regards Michelle
Dr Michelle Miller | CEO & Managing Director | Biotron Limited
Award winning BIT, page-2
-
- There are more pages in this discussion • 127 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BIT (ASX) to my watchlist
|
|||||
Last
2.9¢ |
Change
0.001(3.57%) |
Mkt cap ! $26.16M |
Open | High | Low | Value | Volume |
2.8¢ | 2.9¢ | 2.7¢ | $12.68K | 446.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 289518 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.9¢ | 363210 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 339 | 0.029 |
1 | 45000 | 0.027 |
5 | 289518 | 0.026 |
6 | 278646 | 0.025 |
5 | 699000 | 0.024 |
Price($) | Vol. | No. |
---|---|---|
0.029 | 363210 | 3 |
0.030 | 60000 | 2 |
0.031 | 109129 | 2 |
0.032 | 500000 | 1 |
0.034 | 30000 | 1 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
BIT (ASX) Chart |